Treatment with Ang1-7 after hypoxia initiation mitigated PAH, augmented expression of intestinal occludin and ZO-1, partially attenuated disease-associated changes in gut microbiota, and elevated the beneficial metabolites, butyric acid and tryptophan. The gene discussed is OCLN; the disease is pulmonary arterial hypertension.